All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F14%3A10284796" target="_blank" >RIV/00216208:11110/14:10284796 - isvavai.cz</a>

  • Alternative codes found

    RIV/00064165:_____/14:10284796

  • Result on the web

    <a href="http://dx.doi.org/10.1016/j.vaccine.2013.11.049" target="_blank" >http://dx.doi.org/10.1016/j.vaccine.2013.11.049</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1016/j.vaccine.2013.11.049" target="_blank" >10.1016/j.vaccine.2013.11.049</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths

  • Original language description

    Background: Human papillomavirus (HPV) vaccination offers potential for primary prevention of HPV-related pre-cancers and cancers as demonstrated in clinical trials. Mathematical models have estimated the potential real-life impact of vaccination on theburden of cervical cancer (CC). However, these are restricted to evaluations in a limited number of countries. Methods: Potential decline in CC cases and deaths with the AS04-adjuvanted HPV-16/18 vaccine of young girls naive to HPV, was estimated at steady-state (vaccine coverage: 0-100%) based on clinical trial and country-specific incidence data. Data on vaccine efficacy were taken from the end of study PATRICIA trial of the AS04-adjuvanted HPV-16/18 vaccine. The numbers of cases and deaths due to HPV-16/18 were estimated and compared with those due to any HPV type to estimate the additional cases prevented. This difference estimates CC cases and deaths avoided due to protection against non-vaccine HPV types. Cost-offsets due to reduc

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    FK - Gynaecology and obstetrics

  • OECD FORD branch

Result continuities

  • Project

  • Continuities

    N - Vyzkumna aktivita podporovana z neverejnych zdroju

Others

  • Publication year

    2014

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Vaccine

  • ISSN

    0264-410X

  • e-ISSN

  • Volume of the periodical

    32

  • Issue of the periodical within the volume

    6

  • Country of publishing house

    GB - UNITED KINGDOM

  • Number of pages

    7

  • Pages from-to

    733-739

  • UT code for WoS article

    000331501900015

  • EID of the result in the Scopus database